Pricing Log in Create free account
Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue
+3,749.2%
EPS
+549.1%
Free cash flow
+839.7%

Quarter to June 2026, against a year earlier

134.06 1.20 −0.89%
Market cap
$8.8B
P/E
111×
Fwd P/E
31.2×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Protagonist Therapeutics, Inc. (PTGX) revenue by segment, product and region

Annual Quarterly
Download Excel — free account

Where the money comes from and where it goes

Fiscal 2024: revenue by segment, and margins
Single reportable segment 434 100.00%
Gross margin 100.00%
Operating margin 58.20%
Pre-tax margin 64.32%

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022
Single reportable segment 46 434 60 27
Revenue 46 434 60 27

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.